Pharmaceutical News
-
Teva Announces Positive AJOVY® Results in children and adolescents with episodic migraine (SPACE trial)
Teva Pharmaceutical Industries Ltd. announced that AJOVY® (fremanezumab-vfrm) showed significant efficacy in reducing migraine days in pediatric patients during the Phase 3 SPACE trial, marking it as the first CGRP antagonist approved for both children and adults. The drug was well tolerated, with no new safety concerns identified. Read more
-
Novartis’ Ianalumab Receives FDA Breakthrough Therapy Designation for Sjögren’s Disease
Novartis announced that its therapy Ianalumab has received FDA Breakthrough Therapy designation for Sjögren’s disease, a challenging autoimmune condition. This status is based on promising Phase III trial data. Ianalumab, a monoclonal antibody targeting B-cell activity, may offer the first targeted treatment option for this serious disease if approved. Read more
-
China’s National Medical Products Administration Approves Sanofi’s Myqorzo and Redemplo
On January 15, 2026, Sanofi announced the approval of its innovative medicines Myqorzo and Redemplo by China’s National Medical Products Administration. Myqorzo treats obstructive hypertrophic cardiomyopathy, while Redemplo reduces triglyceride levels in patients with familial chylomicronemia syndrome. These approvals reflect Sanofi’s commitment to addressing unmet medical needs in China. Read more
-
Medical Device Correction Issued for Millions of Abbott FreeStyle Libre 3 and 3 Plus Sensors in US
The FDA issued a safety alert following Abbott’s correction of FreeStyle Libre 3 and 3 Plus glucose monitoring sensors, which may give incorrect low readings due to manufacturing issues. This could lead to dangerous treatment decisions. About three million devices are affected, prompting users to verify their sensors and seek replacements. Read more
-
FDA Approves Zycubo: First-Ever Treatment for Menkes Disease in Children
The FDA has approved Zycubo, the first treatment for Menkes disease in pediatric patients, marking a significant milestone in rare disease management. This subcutaneous injection delivers copper directly into the bloodstream, improving survival outcomes dramatically. This approval provides hope for families affected by the condition, which previously had no available treatments. Read more
-
Pharma Giant Merck Nears $28bn–$32bn Negotiations for Revolution Medicines
Merck & Co. is reportedly in advanced talks to acquire Revolution Medicines for $28-$32 billion. Revolution specializes in targeted cancer therapies, notably its daraxonrasib candidate. This potential deal highlights Merck’s strategy to enhance its oncology portfolio amid patent expirations for Keytruda. The pharmaceutical sector is experiencing increased merger activity as firms pursue innovative growth. Read more